Navigation Links
Therapeutic Proteins to 2016: Drugs, Devices, Diseases, Markets and Forecasts

DUBLIN, March 22, 2013 /PRNewswire/ --

Research and Markets has announced the addition of the "Therapeutic Proteins to 2016. Drugs, Devices, Diseases, Markets and Forecasts" report to their offering.


In recent years, the number of protein-based pharmaceuticals reaching the marketplace has increased exponentially. The clinical application of these drugs is limited by a lack of desirable attributes for adequate absorption or distribution.

It therefore becomes critical to formulate these drugs into safe, stable and efficacious delivery systems. Because these drugs face formidable enzymatic and penetration barriers when administered orally, peptide and protein drugs continue to be developed almost exclusively for parenteral administration.

These combination drug-device products, where the drug and device are clinically tested and approved as a single product entity, are becoming one of the fastest new drug categories. The growth of protein drug products is having a significant effect on the way drugs and devices are developed.

Cooperation between device designers and drug developers is occurring much earlier in the drug development cycle, allowing device designs in many cases to be tailored to the bioavailability targets and pharmacokinetic profiles of specific drug therapies.


- Analyzes approved therapeutic protein products and pipeline candidates and assesses the market potential for existing and probable future protein drug

- Examines protein delivery design issues, packaging, distribution and technology factors

- Assesses the role of protein formulation decisions on therapeutic protein commercialization and market potential

- Examines historical protein drug data for nine major therapeutic segments and provides forecasts by disease segment to 2016

- Profiles therapeutic protein companies, their commercial products, product development activity, and business strategies

Key Topics Covered:

Executive Summary

Protein Therapeutics Market Dynamics

Therapeutic Protein Commercialization - Success Factors

Protein Drugs - Drug Classes and Therapeutic Targets

Protein Drug Therapeutics - Disease Segment Analysis & Forecasts

Market and Regulatory Factors

Protein Drug Therapeutics - Company Profiles

For more information visit

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood , Senior Manager.
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +1-353-1-481-1716

Sector: Pharmaceuticals

SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DART Therapeutics Develops Drug Candidate for Duchenne Muscular Dystrophy
2. Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
3. First Patients Dosed in Proof-of-Concept Clinical Study of Alder Biopharmaceuticals Lead Therapeutic Candidate for Treatment of Migraine, ALD403
4. Research and Markets Announces the Release of Autoimmune Disease Therapeutics to 2016. Targets, Technologies, Therapies, Markets and Opportunities
5. Mast Therapeutics Reports Fourth Quarter And Full Year 2012 Financial Results
6. Echo Therapeutics Achieves ISO 13485 Certification
7. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
8. Echo Therapeutics Appoints Robert Doman to Board of Directors
9. Autoinjectors to 2018 Devices, Therapeutics, Markets, Strategies and Prospect
10. ADVENTRX Completes Name Change To "Mast Therapeutics, Inc."; New Ticker Symbol: "MSTX"
11. Cell Therapeutics to Present at the ROTH Capital Partners 25th Annual Growth Stock Conference
Post Your Comments:
(Date:11/30/2015)... LONDON and BOSTON , ... to research and develop potential new medicines directed at ... multiple therapeutic areas. --> PFE ) to ... to 10 G protein-coupled receptor (GPCR) targets across multiple ... clinical-stage GPCR structure-guided drug discovery and development company and ...
(Date:11/30/2015)... Israel , Nov. 30, 2015  OticPharma, ... acquiring and developing innovative therapies for ear, nose, and ... Keith A. Katkin as chairman of the company,s ... chief executive officer for OticPharma, Ltd.  "Keith brings a ... he will be able to share this experience and ...
(Date:11/30/2015)... SHELTON, Connecticut , November 30, 2015 ... Kentucky Breast Care has entered into a ... women,s healthcare practice. This will allow Kentucky Breast Care ... and offer exceptional care for their patients. ... Kentucky Breast Care has entered into a ...
Breaking Medicine Technology:
(Date:11/30/2015)... , ... November 30, 2015 , ... ... – Kreithen”), one of the leading plastic surgery practices in Florida, is proud ... chosen to consult for surgical innovations giant Ethicon Inc., a Johnson & Johnson ...
(Date:11/30/2015)... ... November 30, 2015 , ... The successful filing of an Investigational New ... is so important to this key industry segment, Regis Technologies has decided to sponsor ... December 4th at 11am EST. , Federal law does not allow new drugs to ...
(Date:11/30/2015)... ... November 30, 2015 , ... Healthjump, Inc. announced ... a Healthcare IT consulting, development and support company. The purchase will expand the ... within DataTrade to extend the services currently provided by Healthjump. , ...
(Date:11/30/2015)... ... , ... GKhair & Tibolli team members and artists were excited and proud ... 8th and 9th at the Puerto Rico Convention Center, San Juan Puerto Rico. The ... of the line fashion journalists. The San Juan Beauty Show carries immense credibility among ...
(Date:11/30/2015)... Georgia (PRWEB) , ... November 30, 2015 , ... ... for healthcare professionals worldwide today released the results of a survey of educational ... East and Africa found a growing global demand for high quality online and ...
Breaking Medicine News(10 mins):